New vitamin d pill aims to tame parathyroid glands in dialysis patients
NCT ID NCT03602261
First seen Apr 18, 2026 · Last updated Jun 22, 2026 · Updated 10 times
Summary
This phase 2 study tested a weekly extended-release capsule of calcifediol (CTAP101) in 44 adults with chronic kidney disease on hemodialysis who also had vitamin D insufficiency and secondary hyperparathyroidism. The goal was to see if the drug could raise vitamin D levels and lower parathyroid hormone. The trial was terminated early, so results are incomplete.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
AKDHC Medical Research Services
Peoria, Arizona, 85381, United States
-
AKDHC Medical Research Services
Phoenix, Arizona, 85027, United States
-
AKDHC Medical Research Services
Phoenix, Arizona, 85035, United States
-
AKDHC Medical Research Services
Phoenix, Arizona, 85258, United States
-
California Institute of Renal Research CKD/Dialysis & Transplant Division
La Mesa, California, 91942, United States
-
Hacienda Dialysis Center
Hacienda Heights, California, 91745, United States
-
Kidney & Hypertension Specialists
San Antonio, Texas, 78207, United States
-
Laurel Canyon Dialysis, LLC
Sun Valley, California, 91352, United States
-
Long Beach Quest Dialysis Center
Long Beach, California, 90807, United States
-
North America Research Institute, Inc.
San Dimas, California, 91773, United States
-
Northshore University Health
Evanston, Illinois, 60201, United States
-
Ontario Dialysis Center
Ontario, California, 91762, United States
-
Renal and Transplant Associates of New England
Springfield, Massachusetts, 01107, United States
-
Research by Design, LLC
Chicago, Illinois, 60643, United States
-
Southwest Houston Research LTD
Houston, Texas, 77099, United States
-
Southwest MS Nephrology
McComb, Mississippi, 39601, United States
-
University of Colorado Denver Anschutz Medical Campus
Aurora, Colorado, 80045, United States
-
WCCT Global, Inc.
Cypress, California, 90630, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Calcifediol (CTAP101) extended-release capsules
What this could lead to
If successful, this could offer a new treatment option to manage secondary hyperparathyroidism in kidney disease patients on dialysis.
What could go wrong
This was a small, early-phase trial that was terminated, so results are limited. The treatment may not prove effective or safe in larger studies.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.